Westpac Banking Corp increased its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 32.9% during the second quarter, Holdings Channel reports. The fund owned 4,274 shares of the biopharmaceutical company’s stock after buying an additional 1,057 shares during the period. Westpac Banking Corp’s holdings in Alnylam Pharmaceuticals were worth $237,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of ALNY. Nisa Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth $128,000. Janney Montgomery Scott LLC bought a new position in Alnylam Pharmaceuticals during the second quarter worth $223,000. Seven Eight Capital LLC raised its position in Alnylam Pharmaceuticals by 200.0% in the first quarter. Seven Eight Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,800 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter worth $175,000. Finally, BlueMountain Capital Management LLC raised its position in Alnylam Pharmaceuticals by 89.3% in the first quarter. BlueMountain Capital Management LLC now owns 3,179 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,500 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) opened at 34.27 on Friday. The company’s 50 day moving average price is $70.69 and its 200-day moving average price is $66.05. The company’s market cap is $2.94 billion. Alnylam Pharmaceuticals Inc. has a one year low of $33.16 and a one year high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The firm earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter last year, the business posted ($0.85) earnings per share. The firm’s revenue was up .2% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.68) EPS for the current fiscal year.
A number of research analysts have weighed in on the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Leerink Swann reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, June 12th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, June 27th. Finally, Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 11th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $80.88.
In related news, CEO John Maraganore sold 30,151 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.